Full text is available at the source.
Abstract
RNA vaccines are highlighted as flexible tools for rapid-response vaccination and therapy.
- Nucleoside-modified mRNA vaccines encapsulated in lipid nanoparticles have shown significant success during the COVID-19 pandemic.
- Molecular design improvements include codon and sequence optimization, as well as chemical modifications.
- Delivery optimization strategies are being explored, including lipid nanoparticles, virus-like particles, and targeted systems.
- Clinical examples in oncology demonstrate the potential of personalized neoantigen approaches and combination therapies.
- Early preclinical studies indicate possibilities for tolerance induction and localized protein replacement.
Simplified